Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tourmaline Bio, Inc. - Common Stock
(NQ:
TRML
)
47.98
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 27, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tourmaline Bio, Inc. - Common Stock
< Previous
1
2
Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated (NYSE - CMA), Veeco Instruments Inc. (Nasdaq - VECO), Tourmaline Bio, Inc. (Nasdaq -
October 17, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRML, CCRD, PBBK on Behalf of Shareholders
October 09, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates FSFG, ARIS, TRML on Behalf of Shareholders
October 07, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated (NYSE - CMA), Veeco Instruments Inc. (Nasdaq - VECO), Tourmaline Bio, Inc. (Nasdaq -
October 07, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
October 06, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WOW, PRO, TRML, PGRE on Behalf of Shareholders
September 22, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: PROS Holdings, Inc. (NYSE – PROS), Paramount Group, Inc. (NYSE – PGRE), Tourmaline Bio, Inc. (Nasdaq - TRML), WideOpenWest, Inc. (NYSE - WOW)
September 22, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PGRE, WOW, TRML, BTBD on Behalf of Shareholders
September 17, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paramount Group, Inc. (NYSE – PGRE), Tourmaline Bio, Inc. (Nasdaq - TRML), BT Brands, Inc. (Nasdaq - BTBD), WideOpenWest, Inc. (NYSE - WOW)
September 17, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
September 11, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRML, WOW, BTBD, WKHS on Behalf of Shareholders
September 09, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Tourmaline Bio, Inc. (Nasdaq - TRML), BT Brands, Inc. (Nasdaq - BTBD), WideOpenWest, Inc. (NYSE - WOW), Workhorse Group Inc. (Nasdaq - WKHS)
September 09, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders
September 09, 2025
From
Halper Sadeh LLC
Via
Business Wire
Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders
September 09, 2025
From
The Ademi Firm
Via
Business Wire
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
September 09, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
August 31, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 13, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
May 20, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
May 19, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 02, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 13, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
March 03, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
January 27, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
January 10, 2025
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
December 10, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
November 14, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
October 31, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
October 15, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
October 11, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
